December 1, 2021
Nippon Shinyaku said on November 29 that it has commenced a Managed Access Program, a paid supply scheme, for its Duchenne muscular dystrophy (DMD) treatment Viltepso (viltolarsen) in countries where the drug is not commercially available. Viltepso is currently approved...read more